基于药代动力学、安全性和有效性数据论证瑞博西利在晚期乳腺癌肾功能不全患者中的剂量
该研究整合专项肾功能不全研究及6项肿瘤临床试验的药代动力学、安全性和有效性数据,评估瑞博西利在肾功能不全患者中的影响并确定剂量建议。结果显示轻中度肾功能不全患者无需调整剂量,重度肾功能不全患者建议降低剂量。
要点
- 轻中度肾功能不全患者使用瑞博西利无需调整剂量。
- 重度肾功能不全患者建议降低瑞博西利剂量。
- 整合临床药理学与患者试验数据可支持肾功能不全剂量论证。
核心结论
- 轻中度肾功能不全患者无需调整瑞博西利剂量,重度肾功能不全患者建议降低剂量。
研究设计与样本
- 整合一项在非癌症受试者中开展的I期专项肾功能不全研究及六项癌症患者I-III期试验的药代动力学、安全性和有效性数据。
主要发现
- 在专项肾功能不全研究中,单次400 mg剂量后肾功能不全受试者的瑞博西利暴露高于肾功能正常者。
- 在患者试验中,按推荐起始剂量600 mg给药后,轻中度肾功能不全癌症患者与肾功能正常患者的单次及稳态暴露相当。
- 模型预测的晚期乳腺癌患者稳态暴露在各肾功能组间也相似。
- 晚期乳腺癌患者中,不同肾功能队列(正常/轻度/中度)的无进展生存期相似,安全性总体一致。
关键数值与推荐
- 轻中度肾功能不全患者无需调整瑞博西利剂量。
- 重度肾功能不全患者建议降低瑞博西利剂量。
临床怎么用
- 临床用药时,轻中度肾功能不全的晚期乳腺癌患者可按推荐剂量使用瑞博西利,无需调整。
- 重度肾功能不全患者应降低瑞博西利剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Renal impairment is common in patients with cancer and can alter the PK and thus the safety and efficacy of drugs. We assessed the impact of renal impairment during treatment with ribociclib, a cyclin-dependent kinase 4/6 inhibitor, and determined dose recommendations for patients with advanced breast cancer with renal impairment. METHODS: A comprehensive assessment integrating pharmacokinetic, safety, and efficacy data from a phase I dedicated renal impairment study in non-cancer subjects and six phase I-III trials in patients with cancer was performed. RESULTS: Ribociclib showed higher pharmacokinetic exposure in subjects with renal impairment than those with normal renal function following a single 400-mg dose in the dedicated renal impairment study. However, in patient trials, both single-dose and steady‑state ribociclib exposure was comparable between patients with cancer with mild/moderate renal impairment and those with normal renal function following the recommended starting dose of 600 mg. Model-predicted steady‑state exposure in patients with advanced breast cancer was also similar across the renal function groups. Progression-free survival was similar and safety profiles were generally consistent across the renal cohorts (normal/mild/moderate) in patients with advanced breast cancer, with low-grade and manageable adverse events, demonstrating a positive benefit-risk profile. CONCLUSIONS: From the collective evidence and considering a real-world clinical setting, no dose adjustment is recommended for patients with mild/moderate renal impairment, whereas a reduced dose is recommended for patients with severe renal impairment. This report presented a holistic and innovative strategy to determine dose in patients with renal impairment and demonstrated the effectiveness of integrating the data of both a clinical pharmacology study and patient trials to justify doses in patients with renal impairment. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifiers: NCT02431481, NCT01958021, NCT02422615, NCT02278120, NCT01237236, NCT01898845, NCT01872260.
引用
- Ji Y, Yartsev V, Quinlan M, et al. Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials. Clin Pharmacokinet. 2023. PMID: 36800111. doi:10.1007/s40262-022-01206-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。